Comparative tolerability, safety and efficacy of tablet formulations of twice-daily clarithromycin 250 mg versus once-daily extended-release clarithromycin 500 mg in pediatric and adolescent patients.
Clarithromycin is widely used to treat respiratory tract and superficial skin infections in pediatric and adult populations. Using clinical endpoints and 7-day therapy, we compared the efficacy of clarithromycin 250 mg tablets given twice daily versus clarithromycin 500 mg extendedrelease tablets given once daily in ambulatory children and adolescents 6 to 16 years old. Of the 199 evaluable patients, 124 were infected with group A streptococcal pharyngitis, 39 with sinusitis, 21 with ambulatory pneumonia, and 15 with superficial skin infections. The overall cure rate exceeded 90% for each treatment group. Discontinuation rates and adverse events were 4.5% and 24.6%, respectively.
Block
Stan L
SL
201 South 5th Street, Bardstown, KY 40004, USA.
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D002626:Chemistry, Pharmaceutical; D002648:Child; D017291:Clarithromycin / Q000008:administration & dosage* / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D010612:Pharyngitis / Q000188:drug therapy; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D012852:Sinusitis / Q000188:drug therapy; D017192:Skin Diseases, Bacterial / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013607:Tablets; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D013607:Tablets; D017291:Clarithromycin